Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rating Upgraded by Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

KNSA has been the subject of several other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a report on Monday, October 13th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.86.

Kiniksa Pharmaceuticals International Trading Up 0.4%

Shares of NASDAQ:KNSA opened at $38.93 on Friday. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $39.79. The business has a fifty day simple moving average of $36.42 and a 200 day simple moving average of $30.34. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of 973.49 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 121,248 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.90, for a total value of $4,716,547.20. Following the transaction, the chief executive officer directly owned 111,794 shares in the company, valued at approximately $4,348,786.60. The trade was a 52.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 905,298 shares of company stock valued at $32,343,574. Company insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth about $301,000. GAMMA Investing LLC grew its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares in the last quarter. Deutsche Bank AG grew its position in Kiniksa Pharmaceuticals International by 177.1% during the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after buying an additional 252,125 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $1,184,000. Finally, Invesco Ltd. grew its position in Kiniksa Pharmaceuticals International by 137.4% during the first quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after buying an additional 19,384 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.